在NSCLC中,GPRC5A促进了帕克利塔塞尔耐药性和葡萄糖含量
Yan Wang1, Liang Gao2, Feiyu Wang2
1Intensive Care Unit, Department of Respiratory Medicine, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing.
Anti-cancer drugs
|April 11, 2024
概括
研究人员确定G蛋白结合受体A类 (GPRC5A) 是抗帕克利塔塞尔肺癌的关键因素. 针对GPRC5A可能为耐药肺癌患者提供新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 肺癌是全球癌症死亡的主要原因之一.
- 帕克利塔塞尔是肺癌的主要化疗方法,但耐药性是一个重大的临床挑战.
- 改变癌细胞代谢,包括增加葡萄糖吸收,与药物耐药性有关.
研究的目的:
- 为了确定与肺癌中帕克利塔塞尔耐药性相关的分子标.
- 研究G蛋白结合受体A类 (GPRC5A) 在帕克利塔塞尔耐药性和癌症代谢中的作用.
- 评估GPRC5A作为克服帕克利塔塞尔耐药性的潜在治疗标.
主要方法:
- 建立抗帕克利塔塞尔的肺癌细胞系.
- 对基因表达数据库 (Gtex,Oncomine,GEO) 的生物信息分析.
- 定量实时PCR (qPCR),西式涂抹和siRNA介导的基因沉默.
- 细胞计数套件-8 (CCK-8) 测试细胞活力和葡萄糖含量测量.
主要成果:
- 耐帕克利塔塞尔肺癌细胞表现出葡萄糖含量增加.
- 在耐药肺癌数据集和细胞系中,GPRC5A被确定为显著上调的基因.
- 抑制GPRC5A表达减少了帕克利塔塞尔耐药性和葡萄糖吸收.
- 网氨酸治疗增加了GPRC5A蛋白水平和葡萄糖含量.
- 肺癌患者高GPRC5A表达与较低的生存率相关.
结论:
- 在肺癌中,GPRC5A对帕克利塔塞尔耐药性和改变葡萄糖代谢的发展起着至关重要的作用.
- 在肺癌患者中,GPRC5A代表了克服获得的帕克利塔塞尔耐药性的有前途的治疗标.
- 需要进一步的临床前研究来探索针对GPRC5A的治疗方法.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K